Sector
PharmaceuticalsOpen
₹224.1Prev. Close
₹229.35Turnover(Lac.)
₹117.44Day's High
₹246.7Day's Low
₹221.5552 Week's High
₹26252 Week's Low
₹137.1Book Value
₹106.86Face Value
₹5Mkt Cap (₹ Cr.)
703.4P/E
0EPS
0Divi. Yield
0.5311 Aug 2023
12:00 AM
AGM
Announcement Date: 11 Aug, 2023
17 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
29 May 2023
12:00 AM
Dividend
Dividend Amount: 1.25
Record Date: 22 Sep, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 14.14 | 14.13 | 14.42 | 14.42 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 319.64 | 381.55 | 356.02 | 298.18 |
Net Worth | 333.78 | 395.68 | 370.44 | 312.6 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|---|
Revenue | 387.96 | 372.82 | 299.26 | 19.35 |
yoy growth (%) | 4.06 | 24.57 | 1,446.28 | 54.73 |
Raw materials | -144.19 | -123.64 | -82.67 | 0 |
As % of sales | 37.16 | 33.16 | 27.62 | 0 |
Employee costs | -59.36 | -57.49 | -50.03 | -5.67 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|---|
Profit before tax | 42.56 | 63.22 | 47.54 | -25.64 |
Depreciation | -23.67 | -19.03 | -14.93 | -3.78 |
Tax paid | -12.32 | -11.26 | 16.12 | 22.97 |
Working capital | 15.97 | 18.66 | 5.68 | 214.15 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 4.06 | 24.57 | 1,446.28 | 54.73 |
Op profit growth | -18.97 | 34.86 | -1,216.24 | -33.65 |
EBIT growth | -26.46 | 21.59 | -790.19 | -24.49 |
Net profit growth | -41.81 | -18.37 | -2,484.03 | -88.94 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 335.66 | 349.94 | 398.52 | 377.29 | 292.95 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 335.66 | 349.94 | 398.52 | 377.29 | 292.95 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 11.81 | 8.6 | 8.14 | 8.25 | 12.32 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.45 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,520.1 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.15 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.6 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,639.05 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Director
Satish Varma
Company Sec. & Compli. Officer
Srikant N Sharma
Executive Vice Chairman & WTD
Krishna Datla
Non Executive Director
Rajeshwari Datla
Chairman & Independent Directo
Sanjay Buch
Independent Director
Vinayak Hajare
Independent Director
Gopakumar G Nair
Executive Director
ANUPAMA DATLA DESAI
Independent Director
Rajashri Santosh Kumar Ojha
Managing Director
Prashant Nagre
Independent Director
Pramod Kasat
Chairman
Pradeep Manjunath Chandan
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Fermenta Biotech Ltd
Summary
Promoted by a technocrat, D V K Raju, Duphar-Interfran (DIL) was incorporated in May 51 as International Franchises Pvt Ltd. In the initial years, the company manufactured and sold toothpaste, anti-septic lotion and pharmaceutical specialities on a loan-licence basis. It entered into collaborations with Philips-Duphar, Amsterdam (Solvay Duphar), and the Crookes Laboratories, London. These collaborators participated in the equity capital of the company to the extent of 25% each.The company changed its name to Crookes Interfran on 19 Apr.63. In 1964, it entered into a collaboration with Solvay Duphar to manufacture vitamin D3. To associate fully with its research-oriented collaborators, in May 71, it changed its name to Duphar-Interfran. In 1976, it entered into another collaboration with Solvay Duphar to manufacture isoxypurine hydrochloride -- a vasodilator. In 1976, in compliance with the FERA, the foreign collaborators reduced thier stake to 38.86%.DIL came out with a rights issue in May 95 to augment long-term resources and working capital requirements. The company also sold its popular analgesic brand Crocin to Smithkline Beecham Pharmaceuticals. It also sold another OTC brand, Lacto-Calamine lotion to Nicholas Piramal to concentrate on the core business of ethical drugs.As per the Scheme of Arrangement, the pharma business of the company has been transferred to a new company called Duphar Pharma India. The Company has made investments in unutilised premises at Thane to c
Read More
What is the Fermenta Biotech Ltd share price today?
The Fermenta Biotech Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹239 today.
What is the Market Cap of Fermenta Biotech Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Fermenta Biotech Ltd is ₹703.40 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Fermenta Biotech Ltd?
The PE and PB ratios of Fermenta Biotech Ltd is 0 and 2.15 as of 22 Jul ‘24
What is the 52 Week High and Low of Fermenta Biotech Ltd?
The 52-week high/low is the highest and lowest price at which a Fermenta Biotech Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Fermenta Biotech Ltd is ₹137.1 and ₹262 as of 22 Jul ‘24
What is the CAGR of Fermenta Biotech Ltd?
Fermenta Biotech Ltd's CAGR for 5 Years at -2.66%, 3 Years at -10.43%, 1 Year at 66.68%, 6 Month at 44.56%, 3 Month at 35.19% and 1 Month at 34.63%.
What is the shareholding pattern of Fermenta Biotech Ltd?
The shareholding pattern of Fermenta Biotech Ltd is as follows:
Promoters - 62.06 %
Institutions - 0.00 %
Public - 36.05 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
